180 Life Sciences Corp Stock Price, News & Analysis

180 Life Sciences Corp. (NASDAQ: ATNF) announced positive findings from a study by Oxford researchers indicating that anti-TNF treatment (adalimumab) is likely cost-effective for early-stage Dupuytren's disease, impacting over 5 million people in the UK. The study, led by Professor Jagdeep Nanchahal, revealed that adalimumab significantly reduces disease symptoms and may cost £14,593 per QALY gained, below the NHS threshold of £20,000. Dr. James Woody emphasized the importance of these findings for potential market accessibility and ongoing partnership discussions.

180 Life Sciences Corp. (NASDAQ: ATNF), a clinical-stage biotechnology firm, provided an update to stockholders highlighting progress in its clinical development programs targeting Dupuytren’s disease and other conditions. The company is conducting Phase 2 trials, with promising data reported in The Lancet Rheumatology about anti-TNF therapy potentially preventing disease progression. A meeting with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) is scheduled for Q4 2022 to discuss regulatory pathways for Dupuytren’s therapy. The company is also advancing trials for frozen shoulder and postoperative cognitive delirium.

180 Life Sciences Corp. (NASDAQ: ATNF) has announced the randomization of the first patient in a clinical trial evaluating the use of anti-tumor necrosis factor (TNF) therapy for pain predominant frozen shoulder. This significant milestone is part of a study funded by the National Institute of Health and Care Research in the U.K. The trial aims to assess whether early injections of anti-TNF can alleviate pain and prevent disease progression. Led by the University of Oxford, the study may pave the way for future phase 3 trials.

180 Life Sciences Corp. (NASDAQ: ATNF) announced a grant from the U.K.'s National Institute for Health and Care Research for a feasibility trial exploring anti-TNF therapy to mitigate post-operative delirium in hip fracture patients aged 60 and over. The trial, led by researchers at the University of Oxford, aims to evaluate the effectiveness of anti-TNF therapy during surgery. Jointly funded by the NIHR and 180 Life Sciences, the trial is expected to begin enrollment in early 2023. This collaboration aims to address a critical unmet medical need, considering the high prevalence of post-operative delirium among older patients.

180 Life Sciences Corp. (NASDAQ: ATNF) announced the closing of its registered direct offering, selling 6,132,076 shares and warrants to buy the same number of shares at $1.06 each. The company aims to use the proceeds for research and development and general corporate needs. The warrants are exercisable after six months and will expire in five years. A.G.P./Alliance Global Partners served as the sole placement agent. This offering was made under an effective shelf registration statement filed with the SEC.

180 Life Sciences Corp. (NASDAQ: ATNF) announced a registered direct offering of 6,132,076 shares and warrants to purchase an equal number of shares at $1.06 per share. The expected gross proceeds are approximately $6.5 million, aimed for research, development, and corporate purposes. The offering closes around July 20, 2022, pending customary conditions. A.G.P./Alliance Global Partners is the placement agent. This issuance follows an effective shelf registration statement filed with the SEC.

180 Life Sciences Corp. (NASDAQ: ATNF) provided an update on its clinical development of a novel therapy for early-stage Dupuytren’s disease. The Phase 2b trial, led by Prof. Jagdeep Nanchahal, successfully met its primary endpoint, showing statistically significant results in nodule hardness (p=0.0002) and size (p=0.0025). The MHRA confirmed the appropriateness of statistical methods used, did not require non-clinical data, and noted a favorable safety profile for adalimumab. The company is focusing on gaining marketing approval from regulatory agencies and expanding its clinical trials.

180 Life Sciences Corp. (NASDAQ: ATNF) has received written feedback from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) and the U.S. FDA regarding its anti-TNF treatment for early-stage Dupuytren’s disease. The MHRA has advised that no further non-clinical studies are needed, but requires evidence validating clinical endpoints. The FDA criticized the proposed outcome measures as inadequate for efficacy demonstration and suggested a pre-investigational new drug meeting for more guidance. Approximately 12 million people in the U.S. suffer from this degenerative condition.

180 Life Sciences Corp. (NASDAQ: ATNF) announced the initiation of consultations with regulatory agencies in the UK and USA regarding their Phase 2b trial for Dupuytren’s disease treatment. Positive data from the trial, published in The Lancet Rheumatology, suggests a potential for earlier intervention in patients with this progressive condition. The FDA will respond to the company’s briefing materials, shaping future development strategies. Currently, no approved treatments exist for early-stage Dupuytren’s disease, indicating a significant market opportunity for the company.